Effects of Banisteriopsis caapi extract on Parkinson's disease

Scientific Review of Alternative Medicine

Volumn 5, Issue 3, 2001, Pages 127-132

  Serrano Dueñas, Marcos ^a   Cardozo Pelaez, Fernando ^a   Sánchez Ramos, Juan R ^a  

^a HOSPITAL CARLOS ANDRADE MARÍN   (Ecuador)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; BANISTERIOPSIS CAAPI EXTRACT; GLUTAMATE RECEPTOR ANTAGONIST; HARMALINE; HARMINE; PLACEBO; PLANT EXTRACT; TETRAHYDROHARMALINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BANISTERIOPSIS CAAPI; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG FORMULATION; DRUG IDENTIFICATION; DYSKINESIA; FEMALE; HALLUCINATION; HUMAN; MALE; MOTOR PERFORMANCE; NAUSEA AND VOMITING; NONHUMAN; PARKINSON DISEASE; PATIENT MONITORING; PLANT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESSNESS; TREMOR; VERTIGO;

EID: 0035372756     PISSN: 10950656     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Drinking the South American hallucinogenic ayahuasca
2. Hallucinogenic plants of the Shuar and related indigenous groups in Amazonian Ecuador and Peru
3. Quantitation of N,N-dimethyltryptamine and Harmala Alkaloids in Human Plasma after Oral Dosing with Ayahuasca
4. Banisterine and Parkinson's disease
5. Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and beta-carboline constituents of ayahuasca
6. Pathophysiology of L-dopa-induced dyskinesias
7. Parkinson's disease. First of two parts
8. Parkinson's disease. Second of two parts
9. Criteria for diagnosis in Parkinson's disease
10. A short test of mental status: Description and preliminary results
11. A rating scale for depression
12. Unified Parkinson's disease rating scale
13. Studies with reversible inhibitors of monoamine oxidase: Harmaline and related compounds
14. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
15. 3H]MK-801 binding to the NMDA receptor in rabbit brain
16. Functional, biochemistry and molecular neuropharmacology of the basal ganglia and motor systems
17. Neurodegeneration and Parkinson's disease
18. Biochemical and functional organization of the basal ganglia
19. Prospects of glutamate antagonists in the therapy of Parkinson's disease
20. The role of striatal glutamate receptors in models of Parkinson's disease
21. Antagonists of glutamate in the treatment of Parkinson's disease: From laboratory to the clinic
22. Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice
23. Glutamatergic drugs in Parkinson's disease
24. The development of animal models for studies in Parkinson's disease
25. Ibogaine neurotoxicity: A re-evaluation
26. A dose-response study of ibogaine-induced neuropathology in the rat cerebellum